Course Agenda

Monday, April 29, 2019
7:30 AM - 8:00 AM
8:00 AM - 10:00 AM
Lecture: Molecular Diagnostics for Lymphoid Malignancies

• Different lymphoproliferative disorders arise from different stages of lymphocyte development. The audience will gain an understanding of how the stage of development and function of normal lymphocytes is related to the malignancies arising these different normal cell types.
• The audience will be able to describe the clinical utility of categorizing different forms of lymphoid malignancies based on information presented about clinical outcomes of different forms of lymphoma/leukemia.
• The audience will be able to choose the best tests for classification and monitoring lymphoproliferative disorders, and be able to describe the mechanics of the various testing methodologies, and the pros and cons of each testing type.

10:00 AM - 10:15 AM

Sponsored by

10:15 AM - 12:15 PM
Lecture: Autologous Hematopoietic Stem Cell Transplantation for Hematologic Malignancies

• Understand how apheresis machines work.
• Identify what diseases in dogs can be treated using apheresis machines, with emphasis on hematologic malignancies.
• Describe how hematopoietic stem cell transplantation can be used to treat and/or cure dogs with lymphoid malignancies.

12:15 PM - 1:00 PM

Sponsored by

1:00 PM - 3:00 PM
Lecture: Molecular Pathology for Disease Diagnosis and Prognostication in Small Animal Cancers

• Understand how tissue collection, fixation and processing can impact molecular diagnostic pathology.
• Have an overview of the current molecular diagnostic techniques, their current uses and limitations.
• Understand how to interpret molecular diagnostic pathology testing, potential pitfalls and limitations.

3:00 PM - 3:15 PM

Sponsored by

3:15 PM - 5:15 PM
Lecture: Immunotherapy of Small Animal Cancers

• Understand the interaction of the immune system and tumor cells during cancer development.
• Describe the key immune cells involved in tumor elimination and in assisting tumor progression.
• Know what cancer immunotherapies have been studied in veterinary medicine and which ones are currently available for use in veterinary medicine
• Become familiar with new immunotherapies that are being researched and tested in veterinary medicine that may appear in the veterinary market at some point.

5:15 PM - 6:00 PM
Welcome Reception

Sponsored by

Welcome Reception
Welcome Reception
Welcome Reception
Tuesday, April 30, 2019
7:25 AM - 11:45 AM
Keynote Series: New and Emerging Therapeutic Advances for Small Animal Cancers
7:30 AM - 8:30 AM
Lecture: Rabacfosadine for Treatment of Lymphoma in Dogs

• Understand the regulatory status of rabacfosadine (Tanovea-CA1) and the legal implications of this status.
• Discuss the mechanism of action, uses and indications of rabacfosadine in dogs.
• Review the published and presented studies regarding rabacfosadine for treatment of canine lymphoma.

8:30 AM - 9:30 AM
Lecture: Unleashing anticancer T cells - is strength in numbers enough?

• Understand how next-generation recombinant technologies are designed to improve patient outcomes.
• Understand the processes of expanding and engineering autologous T cells ex vivo alongside the current and future applications of CAR T cells in the veterinary oncology clinic.
• Recognize the barriers to tumor specific T cells and how future therapeutic strategies must be developed to overcome immunoevasive mechanisms.

9:30 AM - 9:45 AM

Sponsored by

9:45 AM - 10:45 AM
Lecture: Bispecific Targeting of EGFR and UPAR in Canine Hemangiosarcoma

• Understand what Bispecific Ligand Targeted Toxins are and how they work in cancer therapy.
• Understand the rationale for targeting EGFR and uPAR in canine hemangiosarcoma as a therapeutic strategy using adjuvant eBAT, a bispecific EGF angiotoxin.
• Describe the clinical application of eBAT and understand how it differs from other EGFR targeting agents.

10:45 AM - 11:45 AM
Lecture: Beta Adrenergic Antagonism to Treat Canine Hemangiosarcoma

• Understand that adrenergic receptor (AR) antagonists reduce hemangiosaroma cell viability through receptor-independent mechanisms.
• Understand how AR antagonists alter metaabolic pathways to reduce hemangiosarcoma cell viablity.
• Understand that AR antagonists synergize with chemotherapies to kill tumor cells.

11:45 AM - 12:30 PM

Sponsored by

12:30 PM - 2:30 PM
Lecture: Advanced and Functional Cancer Imaging

• Introduce and discuss the currently-available molecular imaging techniques and modalities, providing an overview of advantages, limitations, feasibility/logistics and applicability to veterinary patients.
• Explore the various technological aspects of molecular imaging, including PET/SPECT physics, development of radiopharmaceuticals, hardware/software platforms used in PET/CT, fMRI, HP-MRI, and so on.
• Discuss specific case-based examples of how molecular imaging can inform veterinary cancer patient management.

2:30 PM - 2:45 PM

Sponsored by

2:45 PM - 4:45 PM
Lecture: Cancer Clinical Trial Design, Implementation, and Interpretation

• Instill an understanding of the aailable clinical trial designs used at carious stages of novel drug/technology development and to understand the pros and cons of each approach and under what circumstances they may or may not be appropriate.
• Discuss the mechanistic details and obstacles involved in the implementation of cancer clinical trials.
• Apply these tools to critically assess and interpret clinical trial data.

4:45 PM - 5:00 PM
Final Discussion & Wrap Up